Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
IMMIX BIOPHARMA, INC.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
immixbio.comAI Executive Summary
AI-powered analysis of 8-K filing content
Immix Biopharma announced that NXC-201 achieved an 89% complete response rate in a Phase 2 clinical trial for relapsed/refractory light chain amyloidosis, representing significant progress in their drug development pipeline that could positively impact market position and investor sentiment.
Key Takeaways
NXC-201 demonstrated an 89% complete response rate in 45 patients with relapsed/refractory AL amyloidosis in the Phase 2 NEXICART-2 trial
This clinical milestone represents substantial advancement in Immix Biopharma's research and development efforts
2 more takeaways
Filing Overview
What This Means
IMMIX BIOPHARMA, INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.